Literature DB >> 8115146

Ophthalmic findings in scleromyxedema.

M L Davis1, G B Bartley, L E Gibson, L J Maguire.   

Abstract

PURPOSE: To catalog ophthalmic findings in a cohort of patients with scleromyxedema.
METHODS: Thirty-five biopsy-proven patients with scleromyxedema evaluated at the Mayo Clinic in Rochester, Minnesota, from 1960 to 1991 were identified. Eye examinations were performed on 17 of the patients. Ophthalmic findings not attributable to other systemic or ocular disease were recorded.
RESULTS: The following abnormalities were considered secondary to scleromyxedema: corneal opacities (2 patients), thickened eyebrow or eyelid skin (4 patients), lagophthalmos (1 patient), and ectropion (2 patients). One patient who had concurrent polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome also had choroidal folds and papilledema. A corneal biopsy in one patient disclosed deposits of acid mucopolysaccharide, consistent with one of two previously published cases.
CONCLUSION: A series of patients with scleromyxedema was reviewed. This systemic disorder infrequently may cause visually significant ophthalmic manifestations, including eyelid changes and corneal deposits. Further study is needed to characterize better the nature of the corneal opacities.

Entities:  

Mesh:

Year:  1994        PMID: 8115146     DOI: 10.1016/s0161-6420(94)31339-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  2 in total

1.  Atypical Lichen Myxedematosus: A Case with Remarkable Response to Low Dose Melphalan.

Authors:  Mini Gomathy; Beena Sunny; Krishna Anitha; Sukumarakurup Sreekanth; Kunnaruvath Rajeevan; Soni C Das
Journal:  Indian Dermatol Online J       Date:  2017 May-Jun

2.  Scleromyxedema with subcutaneous nodules: successful treatment with thalidomide and intravenous immunoglobulin.

Authors:  M Dolenc-Voljč; V Jurčić; A Hočevar; M Tomšič
Journal:  Case Rep Dermatol       Date:  2013-11-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.